WO2000056882A1 - 48 human secreted proteins - Google Patents
48 human secreted proteins Download PDFInfo
- Publication number
- WO2000056882A1 WO2000056882A1 PCT/US2000/006791 US0006791W WO0056882A1 WO 2000056882 A1 WO2000056882 A1 WO 2000056882A1 US 0006791 W US0006791 W US 0006791W WO 0056882 A1 WO0056882 A1 WO 0056882A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- sequence
- human
- polypeptide
- polynucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.
- isolated refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered “by the hand of man” from its natural state.
- an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be “isolated” because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.
- the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).
- polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 438 of SEQ ID NO: 15, b is an integer of 15 to 452, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 15, and where b is greater than or equal to a + 14.
- Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out as SEQ ID NO. 116 which corresponds to the Query sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed). It has been discovered that this gene is expressed primarily in Human Fetal
- polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2487 of SEQ ID NO: 16, b is an integer of 15 to 2501, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 16, and where b is greater than or equal to a + 14.
- Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out as SEQ ID NO. 118 which corresponds to the Query sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed). It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares_multiple_sclerosis_2NbHMSP and to a lesser extent in Soares infant brain 1NIB; Spinal cord; Soares_NhHMPu_S 1 ; Heart; H. hypothalamus, frac A,re-excision; prostate-edited; Human Adult Retina; H. Atrophic Endometrium; Stratagene ovary (#937217); Human Prostate Cancer, Stage C fraction; H Female Bladder, Adult; Human Manic Depression Tissue;
- polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 979 of SEQ ID NO:25, b is an integer of 15 to 993, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.
- polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1405 of SEQ ID NO:28, b is an integer of 15 to 1419, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.
- polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 941 of SEQ ID NO:29, b is an integer of 15 to 955, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a
- polynucleotide sequences such as EST sequences
- SEQ ID NO:37 Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome.
- Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out as SEQ ID NO. 150 which corresponds to the Query sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).
- the gene encoding the disclosed cDNA is believed to reside on chromosome 21. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 21.
- polynucleotide sequences such as EST sequences
- SEQ ID NO:55 Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome.
- allelic variants, orthologs, and/or species homologs are also provided in the present invention. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC.
- allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.
- the present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).
- Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these
- variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification.
- the expression vectors will preferably include at least one selectable marker.
- markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria.
- Representative examples of appropriate hosts include, but are not limited to. bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.
- polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., Nature, 310: 105-111 (1984)).
- a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer.
- nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence.
- multimers of the invention may be generated using genetic engineering techniques known in the art.
- polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein inco ⁇ orated by reference in its entirety).
- FISH fluorescence in situ hybridization
- helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses.
- packaging cells Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention. These viral particles are then used to transduce eukaryotic cells, either ex vivo or in vivo. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.
- Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g.
- autoimmune disorders examples include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis.
- allergic reactions and conditions such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polynucleotides or polypeptides, or agonists or antagonists of the present invention.
- these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002366132A CA2366132A1 (en) | 1999-03-23 | 2000-03-16 | 48 human secreted proteins |
AU38857/00A AU3885700A (en) | 1999-03-23 | 2000-03-16 | 48 human secreted proteins |
EP00917963A EP1163332A1 (de) | 1999-03-23 | 2000-03-16 | 48 menschliche, ausgeschiedene proteine |
JP2000606741A JP2002539786A (ja) | 1999-03-23 | 2000-03-16 | 48個のヒト分泌タンパク質 |
US10/105,299 US7368527B2 (en) | 1999-03-12 | 2002-03-26 | HADDE71 polypeptides |
US10/472,965 US20070026454A1 (en) | 1999-03-12 | 2002-03-26 | Human secreted proteins |
US10/472,964 US20070032414A1 (en) | 1999-03-12 | 2002-03-26 | Human secreted proteins |
US10/670,185 US20070015162A1 (en) | 1999-03-12 | 2003-09-25 | 99 human secreted proteins |
US10/670,186 US20070031842A1 (en) | 1999-03-12 | 2003-09-25 | 379 human secreted proteins |
US10/868,184 US20070048818A1 (en) | 1999-03-12 | 2004-06-16 | Human secreted proteins |
US10/994,608 US20070048297A1 (en) | 1999-03-12 | 2004-11-23 | Human secreted proteins |
US11/781,665 US20070298491A1 (en) | 1999-03-12 | 2007-07-23 | Human Secreted Proteins |
US12/753,401 US8410248B2 (en) | 1999-03-12 | 2010-04-02 | HWBAO62 polypeptides |
US13/848,789 US20130203164A1 (en) | 1999-03-12 | 2013-03-22 | Human Secreted Proteins |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12581599P | 1999-03-23 | 1999-03-23 | |
US16994699P | 1999-12-10 | 1999-12-10 | |
US60/125,815 | 1999-12-10 | ||
US60/169,946 | 1999-12-10 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/006822 Continuation-In-Part WO2000056883A1 (en) | 1999-03-12 | 2000-03-16 | 49 human secreted proteins |
PCT/US2000/006828 Continuation-In-Part WO2000056767A1 (en) | 1999-03-12 | 2000-03-16 | 46 human secreted proteins |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/006822 Continuation-In-Part WO2000056883A1 (en) | 1999-03-12 | 2000-03-16 | 49 human secreted proteins |
PCT/US2000/006828 Continuation-In-Part WO2000056767A1 (en) | 1999-03-12 | 2000-03-16 | 46 human secreted proteins |
US95008201A Continuation-In-Part | 1999-03-12 | 2001-09-12 | |
US95008301A Continuation-In-Part | 1999-03-12 | 2001-09-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000056882A1 true WO2000056882A1 (en) | 2000-09-28 |
Family
ID=26823987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/006791 WO2000056882A1 (en) | 1999-03-12 | 2000-03-16 | 48 human secreted proteins |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1163332A1 (de) |
JP (1) | JP2002539786A (de) |
AU (1) | AU3885700A (de) |
CA (1) | CA2366132A1 (de) |
WO (1) | WO2000056882A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140056811A1 (en) * | 2010-12-27 | 2014-02-27 | Compugen Ltd. | New cell-penetrating peptides and uses thereof |
EP2412727B1 (de) * | 2006-02-14 | 2016-06-29 | University Of Tasmania Through The Menzies Research Institute | Von Metallothionein abgeleitete Peptidfragmente |
-
2000
- 2000-03-16 JP JP2000606741A patent/JP2002539786A/ja not_active Withdrawn
- 2000-03-16 EP EP00917963A patent/EP1163332A1/de not_active Withdrawn
- 2000-03-16 AU AU38857/00A patent/AU3885700A/en not_active Abandoned
- 2000-03-16 CA CA002366132A patent/CA2366132A1/en not_active Abandoned
- 2000-03-16 WO PCT/US2000/006791 patent/WO2000056882A1/en not_active Application Discontinuation
Non-Patent Citations (3)
Title |
---|
DATABASE GENBANK ON STP 13 May 1999 (1999-05-13), TP12D07.X1 NCI CGAP GAS4 HOMO SAPIENS CDNA CLONE IMAGE:2187565 3' MRNA SEQUENCE: "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index" * |
DATABASE GENBANK ON STP 16 June 1998 (1998-06-16), OT73E01.S1 SOARES TOTAL FETUS NB2HF8 9W HOMO SAPIENS CDNA CLONE IMAGE: 1622424 3' MRNA SEQUENCE: "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index" * |
DATABASE GENBANK ON STP 28 December 1999 (1999-12-28), XQ96108.X1 NCI. CGAP BRN53 HOMO SAPIENS CDNA CLONE IMAGE:2758503 3' MRNA SEQUENCE: "National Cancer Institute/National Institute of Neurological Disorders and Stroke, Brain Tumor Genome Anatomy Project (CGAP/BTGAP), Tumor Gene Index" * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2412727B1 (de) * | 2006-02-14 | 2016-06-29 | University Of Tasmania Through The Menzies Research Institute | Von Metallothionein abgeleitete Peptidfragmente |
US20140056811A1 (en) * | 2010-12-27 | 2014-02-27 | Compugen Ltd. | New cell-penetrating peptides and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2366132A1 (en) | 2000-09-28 |
EP1163332A1 (de) | 2001-12-19 |
JP2002539786A (ja) | 2002-11-26 |
AU3885700A (en) | 2000-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1175439A1 (de) | 49 humane sekretierte proteine | |
EP1161446A1 (de) | 50 menschliche, ausgeschiedene proteine | |
EP1220947A2 (de) | 50 menschliche ausscheidungsproteine | |
WO2000058334A1 (en) | 50 human secreted proteins | |
WO2000076531A1 (en) | 47 human secreted proteins | |
WO2000055199A1 (en) | 47 human secreted proteins | |
EP1171460A1 (de) | 48 menschliche sekretierte proteine | |
EP1165602A1 (de) | 49 menschliche, sekretierte proteine | |
WO2000061596A1 (en) | 50 human secreted proteins | |
WO2000056751A1 (en) | 50 human secreted proteins | |
EP1165590A1 (de) | 49 menschliche sekretierte proteine | |
EP1163332A1 (de) | 48 menschliche, ausgeschiedene proteine | |
WO2000056880A1 (en) | 50 human secreted proteins | |
WO2000056883A1 (en) | 49 human secreted proteins | |
WO2000061627A1 (en) | 49 human secreted proteins | |
WO2000056881A1 (en) | 48 human secreted proteins | |
EP1169334A1 (de) | 48 menschliche sekretierte proteine | |
EP1169346A1 (de) | 48 menschliche sekretierte proteine | |
WO2000061779A1 (en) | 49 human secreted proteins | |
EP1161448A1 (de) | 49 menschliche sekretierte proteine | |
WO2000061628A1 (en) | 49 human secreted proteins | |
WO2000055200A1 (en) | 50 human secreted proteins | |
WO2000058336A1 (en) | 50 human secreted proteins | |
WO2000058469A1 (en) | 48 human secreted proteins | |
EP1161553A1 (de) | 50 humane sekretierte proteine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 606741 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000917963 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2366132 Country of ref document: CA Ref country code: CA Ref document number: 2366132 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000917963 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000917963 Country of ref document: EP |